Daxor Corporation announced the appointment of Lisa Quartley as its first SVP, Marketing and Commercial Development. Ms. Quartley will be leading a newly focused and reinvigorated commercialization effort for the company's unique diagnostic technology with the goal of making direct blood volume measurement a standard of care. Within the past five years she has led consultancy-side strategic efforts for key brands at Genentech, Novartis, Bristol-Myers Squibb, and Eisai.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.7 USD | +3.19% | +3.19% | +1.04% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.04% | 45.9M | |
+6.49% | 13.08B | |
+11.85% | 9.57B | |
+0.25% | 5.61B | |
+8.56% | 5.6B | |
+7.08% | 5.25B | |
+32.18% | 5.12B | |
+24.64% | 4.77B | |
+2.65% | 4.12B | |
+7.62% | 4.04B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Appoints Lisa Quartley as its First SVP, Marketing and Commercial Development